Some possible molecular mechanisms of VEGF encoding plasmids functioning
- Authors: Grigorian, AS1, Schevchenko KG1
-
Affiliations:
- Human Stem Cells Institute, Moscow
- Issue: Vol 6, No 3 (2011)
- Pages: 24-28
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/121545
- DOI: https://doi.org/10.23868/gc121545
- ID: 121545
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Gene therapeutic approaches to the restoration of the
ischemic tissue perfusion are considered very promising,
but to this time the molecular mechanisms which allow the
therapeutic gene encoding plasmid to transfect the target
cell and underlie the positive clinical effects remain unknown.
In this review the possible molecular mechanisms of the
angiogenic factor VEGF encoding plasmid penetration into the
cytoplasm and the nucleus of the target cell are discussed,
and also the methods for better transfection and the gene of
interest expression are proposed.
ischemic tissue perfusion are considered very promising,
but to this time the molecular mechanisms which allow the
therapeutic gene encoding plasmid to transfect the target
cell and underlie the positive clinical effects remain unknown.
In this review the possible molecular mechanisms of the
angiogenic factor VEGF encoding plasmid penetration into the
cytoplasm and the nucleus of the target cell are discussed,
and also the methods for better transfection and the gene of
interest expression are proposed.
About the authors
A S Grigorian,
Human Stem Cells Institute, MoscowHuman Stem Cells Institute, Moscow
K G Schevchenko
Human Stem Cells Institute, MoscowHuman Stem Cells Institute, Moscow
References
- Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9: 669-76.
- Ferraro B., Cruz Y.L., Baldwin M., Coppola D., Heller R. Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Therapy 2010; 17: 763-9.
- Nikol S. Viral or non-viral angiogenesis gene transfer - New answers to old questions. Cardiovasc. Res. 2007; 73: 443-5.
- Sylven C. Angiogenic gene therapy. Drugs of today 2002; 38: 819-27.
- Деев Р.В., Григорян А.С., Потапов И.В. и др. Мировой опыт и тенденции генной терапии ишемических заболеваний. Ангиология и сосуд. хирургия 2011; 17 (2): 145-54.
- Wiley Gene Therapy Clinical Trials Worldwide. http://www.wiley. com/legacy/wileychi/genmed/clinical/
- Douglas J. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007; 36 (1): 71-80.
- Yang Y., Wilson J.M. Clearance of adenovirus-infected hepatocytes by MHC class I restricted CD4+ CTLs in vivo. J. Immunol. 1995; 155: 2564-9.
- Melillo G., Scoccianti M., Kovesdi I. et al. Gene therapy for collateral vessel development. Cardiovasc. Res. 1997; 35: 480-9.
- Williams P.D., Ranjzad P., Kakar S.J. Development of viral vectors for use in cardiovascular gene therapy. Viruses 2010; 2: 334-71.
- Harris J.D., Lemoine N.R. Strategies for targeted gene therapy. Trends Genet. 1996; 12: 400-5.
- Sinn P.L., Sauter S.L., McCray P.B. Lipoplex size is a major determinant of in vitro lipofection efficiency. Gene Therapy 2005; 12: 1089-98.
Supplementary files
